Novogene
Hummingbird Bioscience, Novogene Partner to ID Cancer Patients With NRG1 Fusions in China
Novogene will use next-generation sequencing to identify solid tumor patients eligible to enroll in clinical trials of Hummingbird's anti-HER3 agent, HMBD-001.